InvestorsHub Logo

north40000

09/17/19 3:48 PM

#214834 RE: north40000 #214829

Besides those pipeline items, if I remember right, GILD has CVD therapies currently tailing off or interested in starting.

Mellowmood77

09/17/19 3:53 PM

#214835 RE: north40000 #214829

Completely de-risked with patent litigation and FDA approval the simple answer is yes.

Over 200 million statin users world wide. If only 1/5 of them get on V we are talking 64 billion in annual revenue.

A company like GILD would be able to get there much faster as well.

If we get a wider than expected label from the FDA.... (stand-alone option) all bets are off.

ggwpq

09/17/19 4:15 PM

#214838 RE: north40000 #214829

north, don't mean to burst the bubble a bit: Gilead slashes cardio salesforce to cope with Letairis, Ranexa generics

https://www.fiercepharma.com/pharma/gilead-laying-off-150-sales-to-deal-letairis-ranexa-patent-expirations